NAP SAPS CSI
Association Between Pain Phenotype and Change in Pain Following Routine Corticosteroid Injection in Patients With Subacromial Pain Syndrome - A Prospective Cohort Study.
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · The Region of Southern Denmark
OTHER_GRANT · Research Council of Lillebaelt Hospital
OTHER_GRANT · Research Council of Lillebaelt Hospital
observational
134
1 country
1
Study Start
October 19, 2026
Actual (reported)Primary Completion
September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this prospective cohort study is to investigate whether pain phenotype is associated with subsequent change in pain intensity after corticosteroid injection given as part of routine care in patients diagnosed with SAPS. The main question it aims to answer is: Does change in shoulder pain from baseline to 4 weeks after corticosteroid injection differ between patients classified as having a nociplastic pain phenotype and those classified as having a non-nociplastic pain phenotype?
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 25, 2026
Actual (reported)August 28, 2026
Actual (reported)October 19, 2026
Actual (reported)September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in shoulder pain during activity between baseline and four weeks after corticosteroid injection as measured by the Visual Analog Scale (VAS)
Pain intensity will be assessed with Visual Analog Scale. Participants will score from 0 (no pain) to 100 (the worst pain they have ever experienced)
4 weeks
Change in shoulder pain during active shoulder elevation between baseline and fifteen minutes after corticosteroid injection as measured by the Visual Analog Scale (VAS)
15 minutes
Change in Shoulder Function between baseline and four weeks after corticosteroid injection as measured by the QuickDASH
4 weeks
Patients with SAPS will be classified according to the IASP criteria for nociplastic pain as having either nociplastic or non-nociplastic pain phenotype
Participants undergo a standardised clinical assessment including medical history, specific orthopedic shoulder test, diagnostic ultrasound and x-ray of the shoulder. Participants are included in this cohort only if they receive a corticosteroid injection as part of usual clinical care. The decision to administer the corticosteroid injection, is made part of usual clinical care and is independent of participation in the study. All corticosteroid injections are administered by experienced clinicians under ultrasound-guidance into the subacromial bursa.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients referred to and evaluated at the specialised shoulder clinic at Vejle Hospital, Denmark
Vejle Hospital
Vejle, Denmark
Thomas Sørensen, PT, Cand.san
University of Southern Denmark
kim G Ingwersen, PT, PhD
University of Southern Denmark
Claus Varnum, Prof., PhD, MD
University of Southern Denmark
Henrik B Vægter, Prof., PT, PhD
Odense University Hospital and University of Southern Denmark
First Submitted
August 25, 2026
First Posted
August 28, 2026
Study Start
October 19, 2026
Actual (reported)Primary Completion
September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
NUMITOR Study: Nummular Headache Iberian Study on the Treatments and Outcomes in Real-World Setting
Proportion af patients with nociplastic and non-nociplastic pain phenotype reporting a clinically relevant improvement in Global Perceived Effect (GPE) four weeks after corticosteroid injection as measured by the GPE scale.
4 weeks
Proportion of patients with nociplastic and non-nociplastic pain phenotype achieving a Patient Acceptable Symptom State (PASS) four weeks after corticosteroid injection as measured by the PASS questionnaire.
4 weeks
Change in shoulder pain at rest between baseline and four weeks after corticosteroid injection as measured by the Visual Analog Scale (VAS)
4 weeks
Contact the study team to confirm eligibility.
Study Completion
November 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 23, 2026
Record last verified: 2026-10
Anonymised patient-level data for the primary objective and explorative outcome will be made available if required by the scientific journal, in which the results of the study are publiched.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: